Episode 23: Inish O'Doherty, PhD, Executive Director, Type 1 Diabetes (T1D) and Transplant Therapeutics (TTC) Consortium at C-Path

episode

TheSugarScience Podcast- curating the scientific conversation in type 1 diabetes not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Trump Secures Greenland Deal They Said Was Impossible 1h 1m · 23 Sep 2026 · Louder with Crowder

Andrew Nabbout, Melbourne City star (24.09.26) 2 min · 23 Sep 2026 · SEN Breakfast

Press Pass | Lawrence on Prep for Patriots' Run Defense, Responding & Building Trust 11 min · 23 Sep 2026 · The Jacksonville Jaguars Official Podcast Network

Karla Bergquist: Specialist Mental Health and Addiction Director on the reduction of Police patient handover times to 30 minutes 2 min · 23 Sep 2026 · The Mike Hosking Breakfast

Iran Enters the War of Words; The AI Agenda for the Trump-Xi Summit 26 min · 23 Sep 2026 · Here's the Scoop

Trump vs. the media 21 min · 23 Sep 2026 · The NPR Politics Podcast

Report any issue

Source

Recorded12 Oct 2020

Publisherfeed.podbean.com ↗

Handlerec:2095165

Show notes

In this episode, Inish O'Doherty joins Monica Westley to discuss his work which focuses on the collaborative selection and development of prognostic biomarkers that can be qualified as Drug Development Tools (DDT) and Novel Methodologies with the FDA and EMA, respectively. Dr. O'Doherty is the Executive Director of C-Path’s Type 1 Diabetes (T1D) and Transplant Therapeutic Consortium (TTC). To learn more about the ongoing research at C-Path, click on the link below C-Path Website

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in